Sunday, 4 October 2026European Markets

CORBION And NORSKE SKOG Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(VIANEWS) - CORBION (CRBN.AS) is among this list of stock assets with the highest dividend rate and return on equity on the Basic Materials sector.

Financial Asset Price Forward Dividend Yield Return on Equity
CORBION (CRBN.AS) €18.52 3.02% 10.89%
NORSKE SKOG (NSKOG.OL) kr40.44 1.65% 19.82%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. CORBION (CRBN.AS)

3.02% Forward Dividend Yield and 10.89% Return On Equity

Corbion N.V. provides lactic acid and lactic acid derivatives, emulsifiers, functional enzyme blends, minerals, vitamins, and algae ingredients in the Netherlands, the United States, Latin America, Asia, rest of North America, and rest of Europe, the Middle East, and Africa. The company offers ingredient solutions made from renewable resources for the food, home and personal care, animal nutrition, pharmaceutical, medical device, and bioplastics markets It markets its products through a network of sales offices and distributors. The company was formerly known as CSM N.V. and changed its name to Corbion N.V. in October 2013. Corbion N.V. was founded in 1919 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, CORBION has a trailing twelve months EPS of €1.11.

PE Ratio

CORBION has a trailing twelve months price to earnings ratio of 16.68. Meaning, the purchaser of the share is investing €16.68 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.89%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.4%, now sitting on 1.51B for the twelve trailing months.

More news about CORBION.

2. NORSKE SKOG (NSKOG.OL)

1.65% Forward Dividend Yield and 19.82% Return On Equity

Norske Skog ASA produces and sells newsprint and magazine papers. It operates in two segments, Publication Paper Europe, and Publication Paper Australasia. The company offers standard newsprint and other papers; and magazine paper comprising super calendared and lightweight coated magazine paper. Its products are primarily used in newspapers and magazines, catalogues, advertising materials, inserts/flyers, supplements, free-sheets, directories, direct mail, and book papers. The company operates in Norway, rest of Europe, North America, Australasia, Asia, and Africa. Norske Skog ASA was founded in 1962 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, NORSKE SKOG has a trailing twelve months EPS of kr9.75.

PE Ratio

NORSKE SKOG has a trailing twelve months price to earnings ratio of 4.15. Meaning, the purchaser of the share is investing kr4.15 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.82%.

Yearly Top and Bottom Value

NORSKE SKOG's stock is valued at kr40.44 at 01:30 EST, way under its 52-week high of kr78.75 and above its 52-week low of kr37.50.

Volume

Today's last reported volume for NORSKE SKOG is 54614 which is 86.32% below its average volume of 399325.

Volatility

NORSKE SKOG's last week, last month's, and last quarter's current intraday variation average was a negative 0.16%, a positive 0.06%, and a positive 1.89%.

NORSKE SKOG's highest amplitude of average volatility was 1.79% (last week), 1.55% (last month), and 1.89% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 25.4%, now sitting on 12.78B for the twelve trailing months.

More news about NORSKE SKOG.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com